Disruptions in amino acid and lipid metabolism may be biomarkers of tardive dyskinesia (TD), according to a study p ...

PTC Therapeutics, Inc. today shared new data being presented from the Phase 3 APHENITY trial and subsequent open-label extension study at the 2025 American College of Medical Genetics and Genomics ...